Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DN022150 Combined With AG Chemotherapy in First-line Advanced Pancreatic Cancer With KRAS G12D Mutation
NCT07656376Phase 3Not yet recruiting
- Sponsor
- Jiangxi Kvvit Pharmaceutical
- Start
- Jun 2027
- Primary completion
- Feb 2029
01
Overview
A Phase 3 trial of DN-022150 in pancreatic cancer (PC), sponsored by Jiangxi Kvvit Pharmaceutical. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
DN-022150
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07656376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656376.